Coriolus versicoloris is one of the well-known traditional medicinal mushrooms used in China for over 2000 years. Polysaccharopeptide (PSP) is identified as the major bioactive component, which can be obtained from the mycelium or fermentation broth of Coriolus versicolor. The polysaccharide content in PSP is ~60% and the peptide content in PSP is ~10-30%. The main monosaccharides found in PSP include glucose, mannose, and a small amount of galactose, xylose, and fucose. β-Glucan is one of the identified components in PSP with the established immunomodulatory function. PSP was approved by the authority and has been used clinically in Japan and China since 1970s. PSP is helpful in improving the survival and quality of life in patients suffering cancers, hepatopathy, hyperlipidemia, chronic bronchitis, and other complex diseases. In this article, the preclinical and clinical studies of PSP are summarized over the past 41 years based on a literature search covering the CNKI, VIP, and Wanfang databases. Current studies support PSP as an immunotherapeutic. PSP activates and enhances the function and recognition ability of immune cells, strengthens the phagocytosis of macrophages, increases the expressions of cytokines and chemokines such as tumor necrosis factor-α (TNF-α), interleukins (IL-1β and IL-6), histamine, and prostaglandin E, stimulates the filtration of both dendritic cells and T-cells into tumors, and ameliorates the adverse events associated with chemotherapy. In recent years, immunotherapy has been widely used in cancer treatment. However, to use PSP as an immunotherapeutic at world stage, further chemical, biochemical and pharmacological studies of PSP are needed.
Keywords: Cancers; Coriolus versicoloris; Hepatopathy; Hyperlipidemia; Immunotherapeutic; Polysaccharopeptide (PSP).
© 2019 Elsevier Inc. All rights reserved.